SUBSCRIBE
SUBSCRIBE

Nick Paul Taylor

Nick is a freelance writer who has been reporting on the global life sciences industry since 2008. With a BSc in biology, Nick writes about the science and business of biopharma and medtech for numerous healthcare publications. He can be reached at nick.paul.taylor@gmail.com or on LinkedIn.

Upward arrow on the background of the flag of China. Paper plane. Economic recovery. Copy space. Business. Background.
Manufacturing
AstraZeneca Building Shanghai Production Plant to Support Cell Therapy Strategy
The company is establishing commercial production capabilities to fuel plans to launch autologous CAR-T cell therapies in China.
March 19, 2026
 · 
2 min read
 · 
Nick Paul Taylor
Photo of Philadelphia downtown city skyline
Manufacturing
TerraPower Commits $450M to Build Radioisotope Production Plant
Constructing the cGMP facility will increase availability of actinium-225, a nuclear material central to radiopharmaceutical programs at AstraZeneca, Bristol Myers Squibb, Eli Lilly and Novartis.
March 18, 2026
 · 
2 min read
 · 
Nick Paul Taylor
FDA signage at its headquarters in Maryland
Manufacturing
FDA Sets Scope for Attempt To Reduce Manufacturing-Related Approval Rejections
Industry and FDA representatives have reached a general agreement on planned pre-submission facility meetings but have expressed different views about the specifics.
March 10, 2026
 · 
2 min read
 · 
Nick Paul Taylor
change business management, businessman turn gear cog to manage change direction arrows, professional or expertise to manage company transformation or implement new process concept vector illustration
Manufacturing
Cell and Gene Therapy Manufacturing Market To Skyrocket to $146B by 2032
Analysts expect the market for manufacturing cell and gene therapies, worth less than $20 billion in 2024, to expand rapidly as approvals drive higher volumes of production.
March 10, 2026
 · 
3 min read
 · 
Nick Paul Taylor
Concept 3d illustration of a collocated containers as though a computer game due to imports tariffs.
Manufacturing
Nonprofit Aims To Modernize Manufacturing by Clearing Capital Hurdle
Industry groups have identified upfront costs as a barrier to streamlining U.S. drugmaking. The nonprofit API Innovation Center has a proposed answer for how to tilt finances in favor of investments in continuous manufacturing.
March 10, 2026
 · 
5 min read
 · 
Nick Paul Taylor
Cooperation concept. Vector of a businessman and a businesswoman connecting the bridge with a missing part
GLP-1s
Novo Nordisk Agrees To Sell GLP-1 Drugs Via Hims & Hers, Ending Dispute
The companies have been embroiled in a row about compounded GLP-1 drugs that escalated to a lawsuit last month. The legal action has now been dropped and the former adversaries have struck a deal that could increase access to Novo’s obesity medicines.
March 9, 2026
 · 
2 min read
 · 
Nick Paul Taylor
Illustration of a yellow envelope on a blue background with a read warning symbol
Supply chain
FDA Sends 30 Warning Letters To Continue Clampdown on Compounded GLP-1s
Having targeted Hims & Hers last year, the FDA has issued warnings to more telehealth companies over their promotion of GLP-1 drugs used to treat diabetes and obesity. In one case, compounded products were linked with multiple ER visits.
March 4, 2026
 · 
2 min read
 · 
Nick Paul Taylor
Downtown Holly Springs , North Carolina,
Manufacturing
How North Carolina Attracted Amgen and Roche To Become a Next-Gen Obesity Drug Production Hotspot
Infrastructure and location have helped make Holly Springs a future hub for obesity drug production, with Amgen and Roche planning to manufacture GLP-1 therapies there to compete in the growing market.
March 3, 2026
 · 
4 min read
 · 
Nick Paul Taylor
Medicine Pill Treatment Seamless Vector Flat Pattern
Manufacturing
Novo Commits $506M To Repurpose Irish Plant for Oral Wegovy Production
As Novo Nordisk continues to lose ground in the obesity market to rival Eli Lilly, the Danish company has started construction projects to establish the ex-Alkermes plant as a hub for supplying oral GLP-1 products to global markets.
March 2, 2026
 · 
2 min read
 · 
Nick Paul Taylor
Creative pattern made with a syringe on pastel pink background. Vaccine for Coronavirus infection. Pandemic concept.
Vaccines
Uncertainty Looms Over Pharma’s Legal Strategy as States Challenge New Vaccine Schedule
The CDC’s changes threaten to cut vaccine sales for makers including Pfizer, Moderna, Merck and more, but a legal expert suspects affected manufacturers will stay on the sidelines rather than back a push to declare the revised schedule unlawful.
February 27, 2026
 · 
2 min read
 · 
Nick Paul Taylor
Aerial photo hotels in Denton, Texas
Manufacturing
Novartis Names Texas City as Location of Its 5th US Radiopharmaceutical Facility
The Denton site is part of a network of manufacturing plants Novartis is building across the U.S. to make cancer drugs that must be shipped to patients quickly.
February 25, 2026
 · 
2 min read
 · 
Nick Paul Taylor
Pictured: Roche tower in Basel, Switzerland
Manufacturing
Roche Seeks Antibiotic Partner as Rising Manufacturing Costs Drive Supply Rethink
The company plans to divest a drug it has made for 40 years, citing increasing production costs and falling prices.
February 24, 2026
 · 
1 min read
 · 
Nick Paul Taylor
Manual worker with protective work gloves holding a yellow safety helmet on a yellow and orange background with copy space and reflections. Concept of workplace security.
Manufacturing
AbbVie Backs Obesity Push With $380M API Production Expansion Project in Illinois
Part of AbbVie’s vow to invest $100 billion in the U.S. over the next decade, the two Illinois facilities will make active ingredients for next-generation neuroscience and obesity drugs when they start operations in 2029.
February 24, 2026
 · 
2 min read
 · 
Nick Paul Taylor
Top view of road and highway junction, intersections and overpasses in vector illustration. Modern roads and transport concept.
Manufacturing
Radiopharmaceutical Sector Shapes Supply Chain Around Fast-Decaying Products
The necessity of delivering medicine days after it’s produced drives decisions about where to build facilities and how to ship radioactive materials to healthcare providers.
February 24, 2026
 · 
3 min read
 · 
Nick Paul Taylor
Illustration of man walking in the beach between two blue seas, surreal abstract path concept
Rare disease
FDA’s Bespoke Pathway To Focus on Gene Editing and RNA-Based Treatments for Rare Diseases
The framework, first introduced by FDA Commissioner Marty Makary and Center for Biologics Evaluation and Research head Vinay Prasad in November, was criticized for lacking detailed guidance. Agency leaders elucidated on the pathway for personalized medicines on Monday.
February 23, 2026
 · 
3 min read
 · 
Nick Paul Taylor
Load More